BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating OfficerGlobeNewsWire • 07/23/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIOGlobeNewsWire • 07/12/24
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - BBIOAccesswire • 06/24/24
Levi & Korsinsky Reminds BridgeBio Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BBIOAccesswire • 06/24/24
Lost Money on BridgeBio Pharma, Inc.(BBIO)? You May Have Been Affected by Fraud- Contact Levi & KorsinskyAccesswire • 06/24/24
BridgeBio Pharma, Inc. (BBIO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their RightsAccesswire • 06/22/24
BridgeBio Pharma, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - BBIOAccesswire • 06/22/24
BridgeBio Pharma, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- BBIOAccesswire • 06/20/24
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire • 06/20/24
ATTENTION BridgeBio Pharma, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your RightsAccesswire • 06/20/24
Lost Money on BridgeBio Pharma, Inc. (BBIO)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire • 06/18/24
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)GlobeNewsWire • 06/18/24
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 06/06/24
BridgeBio Oncology Therapeutics announces first patient dosed with BBO-8520 in the Ph. 1 ONKORAS-101 trial for KRASG12C NSCLCBusiness Wire • 06/06/24
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment ResultsInvestors Business Daily • 06/04/24
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for HypochondroplasiaGlobeNewsWire • 06/04/24
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024GlobeNewsWire • 06/03/24
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)GlobeNewsWire • 05/29/24
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingGlobeNewsWire • 05/24/24
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024GlobeNewsWire • 05/14/24
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified SensitGlobeNewsWire • 05/13/24
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business UpdateGlobeNewsWire • 05/02/24